Aspira Women's Health Inc. 8-K

What Happened

• Aspira Women's Health, Inc. (AWHL) filed an 8-K reporting that on April 26, 2026 it appointed John Strahley as Chief Financial Officer and Chief Accounting Officer effective April 27, 2026. The consulting agreement under which Brian Hungerford served as CFO terminated April 26, 2026 at the request of Hungerford Consulting LLC; Mr. Hungerford is departing for personal reasons.

Key Details

• Appointment effective date: April 27, 2026; departure effective: April 26, 2026.
• Mr. Strahley is 59 and has prior CFO and financial leadership experience (including IsoPlexis Corporation).
• Employment terms: fractional role (minimum 20 hours/week), annualized base salary $167,000, paid semi-monthly; not eligible for company group health/dental/vision/life plans; eligible for the 401(k).
• Equity grant: options to purchase 70,000 shares to be approved by the Board; exercise price = fair market value on grant date. Vesting: 25% after 90 days, remaining 75% vesting monthly over the next nine months; full acceleration of unvested options upon a Change in Control.
• Employment is at-will; no severance or post-termination benefits beyond accrued obligations. The Employment Agreement will be filed as an exhibit to the company’s next Form 10-Q.

Why It Matters

• This 8-K reflects a change in the company’s principal financial and accounting officer, which is a material leadership change for investors to note for financial reporting continuity.
• The CFO role is filled on a fractional basis with a modest cash salary but a significant option award (70,000 shares) that vests quickly and accelerates on a Change in Control, indicating equity alignment without long-term cash commitments.
• Investors should watch subsequent filings (the Form 10-Q with the Employment Agreement exhibit and future disclosures) for any additional details on financial controls, reporting responsibilities, or other changes tied to the CFO transition.